Login to Your Account



AAAS 2017

A fine red line between cures, enhancements using gene editing tech

By Nuala Moran
Staff Writer

Friday, February 17, 2017

BOSTON – The triumph of the Massachusetts Institute of Technology Broad Institute and its spinout company Editas Medicine Inc. in the case of CRISPR/Cas9 gene editing patents could impede the development of human therapies based on the technology, according to one of the leading researchers in the field.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription